Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Salha Mohammed Bujassoum
Observed names:
S A L H A Bujassoum,
S. Bujassoum,
S. M. Bujassoum,
S.M. Bujassoum,
SALHA BUJASSOUM,
Salha Bujassoum,
Salha M. Bujassoum
show all 7
Institutions:
National Center for Cancer Care and Research,
Hamad Medical Corporation
Observed institutions:
University of Toronto,
Yonsei University,
Princess Margaret Cancer Centre,
National Center for Cancer Care and Research,
Yonsei University Health System,
Yonsei Cancer Hospital,
Hamad Medical Corporation
show all 7
ORCID:
0000-0001-5375-7347
Observed ORCID:
0000-0001-5375-7347
OpenAlex ID:
A5005751557
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
2021
·
Joyce O'Shaughnessy
, Susana Sousa
, et al.
·
European Journal of Cancer
·
93
PDF
Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy
2003
·
SALHA BUJASSOUM
, JOSHUA RIFKIND
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
55
Genotype and Phenotype Correlation of Breast Cancer in BRCA Mutation Carriers and Non-Carriers
2017
·
Salha Mohammed Bujassoum
, Hekmet Abubaker Bugrein
, et al.
·
Journal of Cancer Science & Therapy
·
34
Qatar’s Experience With Hereditary Breast and Ovarian Cancer and High Risk Clinic: a Retrospective Study 2013-2016
2017
·
Salha Mohammed Bujassoum
, HekmetAbubaker Bugrein
, et al.
·
International Journal of Research -GRANTHAALAYAH
·
16
PDF
QPGx‐CARES : Qatar pharmacogenetics clinical applications and research enhancement strategies
2024
·
Rania Abdel‐latif
, Radja Badji
, et al.
·
Clinical and Translational Science
·
14
Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)
2023
·
Anas Hamad
, Shereen Elazzazy
, et al.
·
BMC Health Services Research
·
13
PDF
Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis
2025
·
Dina Abushanab
, Shaban Mohamed
, et al.
·
Clinical Drug Investigation
·
11
PDF
Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation
2024
·
Shereen Elazzazy
, Nour Hisham Al-Ziftawi
, et al.
·
Frontiers in Oncology
·
10
Prevalence of homologous recombination deficiency among women with newly diagnosed ovarian, primary peritoneal, and/or fallopian tube cancer: the international HALO study
2025
·
Svetlana Khokhlova
, Manwar Abdulelah Alnaqqash
, et al.
·
International Journal of Gynecological Cancer
·
9
PDF
A Grave Outcome of Posterior Reversible Encephalopathy Syndrome in a Patient Receiving Avastin (Bevacizumab) for Metastatic High-Grade Serous Ovarian Cancer
2015
·
Hind H. Elmalik
, Shereen ElAzzazy
, et al.
·
Case Reports in Oncology
·
8
PDF
Epidemiology of Breast Cancer in Qatar 1999-2002
2004
·
S. M. Bujassoum
, A. A. Gehani
·
Qatar medical journal
·
7
Epidemiology of Breast Cancer in Qatar 1999-2000
2005
·
S. M. Bujassoum
·
Qatar medical journal
·
6
Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy. Retrospective study in early stage ER positive breast cancer
2018
·
Farouq Salih
, Francois Calaud
, et al.
·
Annals of Breast Cancer
·
5
PDF
Li-Fraumeni Syndrome: The Two Faces of a Coin in Myeloid Malignancies
2023
·
Mariem Sidenna
, Reem Al Sulaiman
, et al.
·
Blood
·
4
PDF
Genotype and Phenotype Correlation of Breast Cancer in BRCA Carriers and Non-Carriers
2016
·
Hekmet Bugrein
, Salha Mohammed Bujassoum
·
Qatar Foundation Annual Research Conference (ARC)
·
4
Identifying Lynch Syndrome in Two Families with Classical Hereditary Breast and Ovarian Cancer Syndrome Phenotype: A Case Report
2018
·
Salha Bujassoum
, Reem Alsulaiman
, et al.
·
Journal of Cancer Science & Therapy
·
2
Abstract P3-16-03: Clinical and pharmacoeconomic analyses of CDK4/6 inhibitors use in stage IV breast cancer females in the state of Qatar: A comparative retrospective observational study with cost effectiveness and cost utility analyses
2022
·
Nour Hisham Al-Ziftawi
, Shereen Elazzazy
, et al.
·
Cancer Research
·
1
Erratum
2015
·
Sadahisa Ogasawara
, Masanori Inoue
, et al.
·
Case Reports in Oncology
·
1
PDF
Abstract P3-02-05: Qatar experience of Standard risk breast cancer screening program (BCSP)
2015
·
Salha Bujassoum
, Reena Alassam
, et al.
·
Cancer Research
·
1
Qatar experience of standard risk breast cancer screening program (BCSP).
2014
·
Salha M. Bujassoum
, Reena Alassam
, et al.
·
Journal of Clinical Oncology
·
1
Qatar Experience In Standard Breast Cancer Screening
2014
·
Hekmet Abubaker Bugrein
, Salha Bujassoum
·
Qatar Foundation Annual Research Conference (ARC)
·
1
CLO26-124: Comparative Outcomes of CDK4/6 Inhibitors and Endocrine Therapy in HER2-Low Versus HER2-Negative Metastatic Breast Cancer: A Retrospective Nationwide Cohort Study From Qatar
2026
·
Ahmed Kardousha
, Laila Shafei
, et al.
·
Journal of the National Comprehensive Cancer Network
QIM26-296: Optimizing Chemotherapy Day Care Services Through Workflow Redesign: A Quality Improvement Initiative From Qatar
2026
·
Mohammed Gaber
, Mohamed S. Elkhatim
, et al.
·
Journal of the National Comprehensive Cancer Network
Clinicopathological Characteristics, Prognosis, and Survival Outcomes of Advanced Stage Gastric Cancer with Single- Site Metastasis: Nationwide Real-World Data from Qatar
2026
·
L.A. Zar
, A. Abdalhadi
, et al.
·
Research Square
PDF
Cardiovascular risk assessment and modifying cardiotoxicity in breast cancer patients receiving Anthracyclines and Anti-HER2 Therapy
2025
·
A Al Bulushi
, S A L H A Bujassoum
, et al.
·
European Heart Journal Supplements
Show more works
View as search
Works count:
34
Citation count:
296
H-index:
9
I10-index:
8
Year
Topic
Type